Clinical Trials

By engaging three metabolic receptors at once — GLP-1, GIP, and glucagon — retatrutide represents a genuinely new idea in metabolic pharmacology. Here is what triple agonism means, and what the human data shows so far.

A growth-hormone-releasing peptide backed by large randomized trials and an FDA approval — a look at what a fully developed body of human peptide evidence can look like.